Merck KGaA Joins Hands With Busan On Regenerative Medicine
This article was originally published in PharmAsia News
South Korea's Busan Metropolitan City will sign a memorandum of understanding with (MoU) Merck KGaA to set up a research and development center in the country's second largest city in a bid to join hands with the German pharma giant in the regenerative medicine sector.
You may also be interested in...
With big pharma on board, disappointments like the threatened EU market removal of pioneering Glybera and the Celladon trial failure give the field of gene therapy a bumpy ride after some major highs.
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.